Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Notes Payables (2016 - 2017)

Historic Notes Payables for Bio-Techne (TECH) over the last 4 years, with Q1 2017 value amounting to $14.6 million.

  • Bio-Techne's Notes Payables rose 28282.56% to $14.6 million in Q1 2017 from the same period last year, while for Mar 2017 it was $14.6 million, marking a year-over-year increase of 28282.56%. This contributed to the annual value of $3.8 million for FY2016, which is 658.55% down from last year.
  • Bio-Techne's Notes Payables amounted to $14.6 million in Q1 2017, which was up 28282.56% from $3.6 million recorded in Q4 2016.
  • Bio-Techne's Notes Payables' 5-year high stood at $14.6 million during Q1 2017, with a 5-year trough of $3.0 million in Q1 2015.
  • In the last 4 years, Bio-Techne's Notes Payables had a median value of $3.8 million in 2015 and averaged $5.2 million.
  • Per our database at Business Quant, Bio-Techne's Notes Payables plummeted by 3667.06% in 2015 and then surged by 28282.56% in 2017.
  • Bio-Techne's Notes Payables (Quarter) stood at $6.0 million in 2014, then tumbled by 36.67% to $3.8 million in 2015, then decreased by 5.12% to $3.6 million in 2016, then soared by 305.51% to $14.6 million in 2017.
  • Its Notes Payables stands at $14.6 million for Q1 2017, versus $3.6 million for Q4 2016 and $3.7 million for Q3 2016.